Пирфенидон
Пирфенидон атрибут
| Температура плавления: |
96-97°C |
| Температура кипения: |
329.1±15.0 °C(Predicted) |
| плотность: |
1.137±0.06 g/cm3(Predicted) |
| температура хранения: |
Sealed in dry,Room Temperature |
| растворимость: |
ДМСО: ≥10 мг/мл, растворимый |
| форма: |
Твердый |
| пка: |
-0.16±0.63(Predicted) |
| цвет: |
От белого |
| Растворимость в воде: |
Soluble to 20 mM in water |
| Стабильность:: |
Срок годности 2 года с даты покупки в состоянии поставки. Растворы в ДМСО можно хранить при температуре -20°С до 1 месяца. |
| InChI: |
InChI=1S/C12H11NO/c1-10-7-8-12(14)13(9-10)11-5-3-2-4-6-11/h2-9H,1H3 |
| ИнЧИКей: |
ISWRGOKTTBVCFA-UHFFFAOYSA-N |
| SMILES: |
C1(=O)N(C2=CC=CC=C2)C=C(C)C=C1 |
| Справочник по базе данных CAS: |
53179-13-8(CAS DataBase Reference) |
| FDA UNII: |
D7NLD2JX7U |
| Словарь онкологических терминов NCI: |
pirfenidone |
| Словарь наркотиков NCI: |
pirfenidone |
| Код УВД: |
L04AX05 |
безопасность
- Заявления о рисках и безопасности
- код информации об опасности(GHS)
| символ（GHS） |
|
| сигнальное слово |
Warning |
| Заявление об опасности |
| пароль |
Заявление об опасности |
Класс опасности |
категория |
сигнальное слово |
пиктограмма |
предупреждение |
| H302 |
Вредно при проглатывании. |
Острая токсичность, пероральная |
Категория 4 |
Предупреждение |
|
P264, P270, P301+P312, P330, P501 |
|
| Внимание |
| P301+P312+P330 |
ПРИ ПРОГЛАТЫВАНИИ: Обратиться за медицинской помощью
при плохом самочувствии. Прополоскать рот. |
|
Пирфенидон химические свойства, назначение, производство
Описание
Until recently, IPF therapy consisted of a combination of corticosteroids
and immunosuppressive agents (azathioprine and cyclophosphamide)
to target the inflammation that was believed to be the pathogenic
stimulus.Since IPF is now considered to be predominantly a disorder of
fibroproliferation, agents that intervene in fibrogenesis have moved
to the forefront of treatment options. With demonstrated efficacy in a
bleomycin-induced lung fibrosis animal model, pirfenidone has been
developed and launched as an approved therapy for IPF. Its antifibrotic activity is derived from the inhibition of p38 MAP kinase that is
upstream of transforming growth factor-β (TGF-β), a cytokine implicated
in the stimulation of collagen synthesis and the inhibition of its
degradation. Pirfenidone also inhibits the expression of TNF-α, IL-1,
and ICAM-1, so it possesses the dual benefit of an anti-inflammatory and
antifibrotic agent. This relatively simplistic drug is constructed by the copper-catalyzed reaction of 5-methyl-2(1H)-pyridinone with bromo- or chlorobenzene.
.
Химические свойства
Off-White Solid
Использование
Pirfenidone is in a group of medicines called antifibrotic agents. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It affects your body’s immune system and reduces the amount of fibrosis (scarring) in the lungs. Pirfenidone is one of two medicines that are approved in Canada to treat Idiopathic Pulmonary Fibrosis (IPF). Another name for this medicine is Esbriet.
Определение
ChEBI: A pyridone that is 2-pyridone substituted at positions 1 and 5 by phenyl and methyl groups respectively. An anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis.
Общее описание
Pirfenidone?(5-methyl-1-phenyl-2-[1H]-pyridone) is a synthetic derivative of pyridine.
Биологическая активность
Antifibrotic agent, effective in models of pulmonary and lung fibrosis. Inhibits collagen production and fibroblast proliferation. Regulates cytokine levels following oral administration in vivo . Potent scavenger of free radicals and inhibitor of lipid peroxidation.
Пирфенидон препаратная продукция и сырье
сырьё
препарат
Пирфенидон поставщик
Global( 495)Suppliers
53179-13-8(Пирфенидон)подобный поиск: